Why consider human papillomavirus vaccination in older women?

Gynecologic and Obstetric Investigation

Volumn 70, Issue 4, 2010, Pages 237-243

  Poppe, W A ^a   Simon, P H ^b   De Ridder, M R ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Cervical cancer; Human papillomavirus

Indexed keywords

HEPATITIS A VACCINE; PLACEBO; WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DISEASE COURSE; DRUG EFFICACY; GERIATRICS; GROUPS BY AGE; HEPATITIS A; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; REINFECTION; REVIEW; SEROCONVERSION; SEROLOGY; SEXUALITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; AGE FACTORS; ANTIBODIES, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNITY, INNATE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 78649703605     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314012     Document Type: Review

References (34)

1. Garland SM, Hernandez-Avila M, Wheeler CM, et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943. (Pubitemid 46740303)
2. Ault KA (Future II Study Group): Effect of prophylactic human papillomavirus L1 viruslike-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 2007;369:1861-1868.
3. Villa LL, Ault KA, Giuliano AR, et al: Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006;24:5571-5583.
4. Joura EA for the Future I and II Study Group: Sustained protection by quadrivalent HPV (type 6, 11, 16, 18) vaccine through 4 years against HPV 6/11/16/18-related cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma in situ of the cervix. 19th International Congress on Anti-Cancer Treatment (ICACT), Paris, 2008.
5. Munoz N, Manalastas R Jr, Pitiisuttithurn P, et al: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double blind trial. Lancet 2009;373:1949-1958.
6. Schwarz TF, Spaczynski M, Schneider A, et al: Immunogenicity and tolerability of an HPV 16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-587.
7. Einstein MH: Immune response after primary vaccination course: a comparative trial of two HPV prophylactic vaccines. Abstract O-01.02. 25th Int Papillomavirus Conf, Malmö, 2009.
8. Paavonen J, Jenkins D, Bosch FX, et al: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-2170.
9. Paavonen J, Naud P, Salméron J, et al: Efficacy of human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; doi: 10.1016/S0140-6736 (09) 61248-4.
10. Harper DM, Franco EL, Wheeler CM, et al: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: followup from a randomised control trial. Lancet 2006;367:1247-1255.
11. De Carvalho N, Roteli-Martins C, Teixeira J, Naud P, de Borba P, Zajaf T, Sanchez N, Schuind A: Immunogenicity and safety of HPV 16/18 ASO4-adjuvanted vaccine up to 7.3 years. Abstract P-29-15. 25th Int Papillomavirus Conf, Malmö, 2009.
12. Schiller J, Castellsagué X, Villa L, et al: An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;265: K53-K61.
13. Harper D, Gall S: HPV-007 Efficacy Abstract. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow-up through 6.4 years in women vaccinated with Cervarix. SGO 2008, Tampa, USA.
14. Burk RD, Kelly P, Feldman J, et al: Declining prevalence of cervicovaginal HPV infection with age is independent of other risk factors. Sex Transm Dis 1996;23:3333-3341.
15. Kinlen LJ, Spriggs AJ: Women with positive cervical smears but without surgical intervention: a follow-up study. Lancet 1978; ii: 463-465.
16. Syrjänen K, Hakama M, Saarikoski S, et al: Prevalence, incidence, and estimated lifetime risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Transm Dis 1990;17:15-19.
17. Bory JP, Cucherousset J, Lorenzato M, et al: Recurrent HPV infection detected with HCII assays selects women with normal cervical smears at risk for developing high grade cervical lesions; a longitudinal study of 3091 women. Int J Cancer 2002;102:519-525.
18. Dalstein V, Riethmuller D, Prétet JL, et al: Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106:396-403.
19. Franco EL, Villa LL, Sobrinho JP, et al: Epidemiology of acquisition and clearance of cervical HPV in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-1423.
20. De Sanjosé S, Diaz M, Castellsagué X, et al: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-459.
21. Syrjänen K, Kulmula SM, Shabalova I, et al: Epidemiological, clinical and viral determinants of the increased prevalence of highrisk human papillomavirus (HPV) infections in elderly women. Eur J Gynaecol Oncol 2008;29:114-122.
22. Kjaer S, Høgdall E, Frederiksen K, et al: The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women of a 10-year period. Cancer Res 2006;66:10630-10636.
23. Drumright LN, Gorbach PM, Holmes KK: Do people really know their sex partners? Concurrency, knowledge of partner behavior, and sexually transmitted infections with partnerships. Sex Transm Dis 2004;31:437-442.
24. Johnson A, Mercer C, Erens B, et al: Sexual behaviour in Britain; partnerships, practices and HIV risk behaviours. Lancet 2001;358:1835-1842.
25. Grainge MJ, Seth R, Guo L, et al: Cervical human papillomavirus screening among older women. Emerg Infect Dis 2005;11:1680-1685.
26. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA: Risk of female papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008;197:279-282.
27. Wright TC, Bosch FX: Is viral status needed before vaccination? Vaccine 2008;265:A12-A15.
28. Trottier H, Ferreira S, Prado J C M, et al: HPV in older women is associated with new sexual partners. Abstract 0-06.02. 25th Int Papillomavirus Conf, Malmö, 2009.
29. Carter JJ, Koutsky LA, Hughes JP, et al: Comparison of human papillomavirus types 16, 18. and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-1919.
30. Viscidi RP, Schiffman M, Hildesheim A, et al: Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a populationbased study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13:324-327.
31. Thomas KK, Hughes JP, Kuypers JM, et al: Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000;182:1097-1102.
32. Steele J, Collins S, Wen K, Ryan G, Constandinou-Williams C, Woodman C: Measurement of the humoral immune response following an incident HPV 16 or 18 infection in young women by a pseudovirion-based neutralization antibody assay. Clin Vaccine Immunol 2008;15:1387-1390.
33. Harper DM: Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25. years of age. Gynecol Oncol 2008;110(3S1): S11-S17.
34. Poncelet S: Induction of cervical mucosal HPV IgG in women 15-55 years old following systemic vaccination with GSK's prophylactic cervical cancer candidate vaccine. International Papillomavirus Conference and Clinical Workshop, Beijing, 2007.